The NeoSphere trial [9] and its 5-year analysis [6] showed that neoadjuvant chemotherapy combined with trastuzumab and pertuzumab achieved better pCR, progression-free survival (PFS), and disease-free survival (DFS) than trastuzumab plus chemotherapy, thus launching a new era of dual-HER2 blockade for HER2-positive BC. Here, ERBB2 is linked to breast cancer.